Scilex Holding Company Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Scilex Holding Company (SCLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.96% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-14
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.71%, a 3.64% decline year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 3.85%, a 10.47% decline year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.30%, a 19.11% increase year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.61%, a 50.42% increase year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.22%, a 8.21% increase from fiscal 2023.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.90%, a 1.02% decline from fiscal 2022.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.94%, a 231.09% increase from fiscal 2021.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.19%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | 3.96% 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | 3.71% 10-Q · filed 2026-05-20 | |||||
| 2025-12-31 | 3.44% 10-Q · filed 2026-08-14 | |||||
| 2025-09-30 | 3.57% 10-Q · filed 2025-11-14 | |||||
| 2025-06-30 | 3.67% 10-Q · filed 2025-08-13 | |||||
| 2025-03-31 | 3.85% 10-Q · filed 2025-05-14 | |||||
| 2024-12-31 | 4.22% 10-K · filed 2026-04-10 | |||||
| 2024-09-30 | 3.55% 10-Q · filed 2025-01-17 | |||||
| 2024-06-30 | 4.44% 10-Q · filed 2024-08-13 | |||||
| 2024-03-31 | 4.30% 10-Q · filed 2024-05-13 | |||||
| 2023-12-31 | 3.90% 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | 4.63% 10-Q · filed 2023-11-14 | |||||
| 2023-06-30 | 4.20% 10-Q · filed 2023-08-11 | |||||
| 2023-03-31 | 3.61% 10-Q · filed 2023-05-12 | |||||
| 2022-12-31 | 3.94% 10-K · filed 2024-03-12 | |||||
| 2022-11-10 | 3.91% 10-K · filed 2023-03-07 | |||||
| 2022-09-30 | 4.03% 10-Q · filed 2022-11-04 | |||||
| 2022-06-30 | 3.10% 10-Q · filed 2022-08-12 | |||||
| 2022-03-31 | 2.40% 10-Q · filed 2022-05-16 | |||||
| 2021-12-31 | 1.28% 10-Q · filed 2022-11-04 | |||||
| 2021-12-20 | 1.19% 10-K · filed 2022-02-24 | |||||
| 2021-09-30 | 1.03% 10-Q/A · filed 2021-12-08 | |||||
| 2021-06-30 | 1.00% 10-Q/A · filed 2021-08-24 | |||||
| 2021-03-31 | 1.08% 10-Q · filed 2021-07-23 | |||||
| 2021-01-11 | 0.57% 10-Q · filed 2021-07-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |